HSI announced earlier that the results of half year index review of Hang Seng Shanghai, Shenzhen and Hong Kong innovative drug selection 50 index as of April 30, 2020, including Livzon (01513), Genscript (01548), HANSOH Pharmaceutical (03692), TUL (03933), etc., while removing some of the original list of stocks, Hang Seng Shanghai Shenzhen Hong Kong innovative drug selection 50 index components remain unchanged. The change took effect on June 8.